International Journal of Hematology

, Volume 85, Issue 2, pp 173–174 | Cite as

Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy

  • Seiichi Okabe
  • Tetsuzo Tauchi
  • Yuko Ishii
  • Daigo Akahane
  • Kousuke Nunoda
  • Seiko Honda
  • Tomoiku Takaku
  • Kazuma Ohyashiki
Article

Keywords

Imatinib Imatinib Mesylate Chronic Myeloid Leukemia Patient Imatinib Therapy Imatinib Treatment 

References

  1. 1.
    Kantarjian H, Talpaz M, O’Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome- positive chronic phase chronic myeloid leukemia. Blood. 2004;103:2873–2878.PubMedCrossRefGoogle Scholar
  2. 2.
    O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia. N Engl J Med. 2003; 348: 994–1004.PubMedCrossRefGoogle Scholar
  3. 3.
    Sumi M, Tauchi T, Sashida G, et al. Clinical usefulness of transcription-mediated amplification and hybridization protection assay in imatinib-treated chronic myelogenous leukemia patients. Clin Lab Haematol. 2005;27:416–417.PubMedCrossRefGoogle Scholar
  4. 4.
    Higashi T, Tsukada J, Kato C, et al. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases. Am J Hematol. 2004;76:275–278.PubMedCrossRefGoogle Scholar
  5. 5.
    Cortes J, O’Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood. 2004; 104:2204–2205.PubMedCrossRefGoogle Scholar
  6. 6.
    Mauro MJ, Druker BJ, Maziarz RT. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res. 2004;28(suppl 1):S71-S73.PubMedCrossRefGoogle Scholar
  7. 7.
    Merante S, Orlandi E, Bernasconi P, Calatroni S, Boni M, Lazzarino M. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica. 2005;90:979–981.PubMedGoogle Scholar
  8. 8.
    Ghanima W, Kahrs J, Dahl TG 3rd,Tjonnfjord GE. Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia. Eur J Haematol. 2004;72:441–443.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2007

Authors and Affiliations

  • Seiichi Okabe
    • 1
  • Tetsuzo Tauchi
    • 1
  • Yuko Ishii
    • 1
  • Daigo Akahane
    • 1
  • Kousuke Nunoda
    • 1
  • Seiko Honda
    • 1
  • Tomoiku Takaku
    • 1
  • Kazuma Ohyashiki
    • 1
  1. 1.First Department of Internal MedicineTokyo Medical UniversityTokyoJapan

Personalised recommendations